CY1108562T1 - Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες - Google Patents

Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες

Info

Publication number
CY1108562T1
CY1108562T1 CY20081101296T CY081101296T CY1108562T1 CY 1108562 T1 CY1108562 T1 CY 1108562T1 CY 20081101296 T CY20081101296 T CY 20081101296T CY 081101296 T CY081101296 T CY 081101296T CY 1108562 T1 CY1108562 T1 CY 1108562T1
Authority
CY
Cyprus
Prior art keywords
methods
receptor antagonist
glucocorticoid receptor
preventing weight
weight recovery
Prior art date
Application number
CY20081101296T
Other languages
English (en)
Inventor
Joseph K Belanoff
Alan F Schatzberg
Original Assignee
Corcept Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics, Inc. filed Critical Corcept Therapeutics, Inc.
Publication of CY1108562T1 publication Critical patent/CY1108562T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση, σε γενικές γραμμές, σχετίζεται με τον τομέα της ψυχιατρικής. Συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με την ανακάλυψη πως παράγοντες ικανοί να αναστείλουν την δέσμευση της κορτιζόλης στους υποδοχείς της μπορούν να χρησιμοποιηθούν σε μεθόδους για την πρόληψη πρόσληψης βάρους που προκαλείται από τη χορήγηση αντιψυχωτικής θεραπείας. Η μιφεπριστόνη, ένας ικανός εξειδικευμένος ανταγωνιστής γλυκοκορτικοειδούς υποδοχέα, μπορεί να χρησιμοποιηθεί σε αυτές τις μεθόδους. Η εφεύρεση παρέχει επίσης ένα κιτίο για την πρόληψη της πρόσληψης βάρους από χορήγηση αντιψυχωτικής θεραπείας σε κάποιον άνθρωπο, το οποίο περιέχει έναν ανταγωνιστή γλυκοκορτικοειδούς υποδοχέα και οδηγίες που περιλαμβάνουν ενδείξεις, δοσολογία και πρόγραμμα χορήγησης του ανταγωνιστή γλυκοκορτικοειδούς υποδοχέα.
CY20081101296T 2001-07-23 2008-11-12 Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες CY1108562T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30769301P 2001-07-23 2001-07-23
EP02750269A EP1408981B1 (en) 2001-07-23 2002-07-22 Methods for preventing antipsychotic-induced weight gain

Publications (1)

Publication Number Publication Date
CY1108562T1 true CY1108562T1 (el) 2014-04-09

Family

ID=23190816

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101296T CY1108562T1 (el) 2001-07-23 2008-11-12 Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες

Country Status (20)

Country Link
US (1) US6680310B2 (el)
EP (1) EP1408981B1 (el)
JP (2) JP2004537563A (el)
KR (1) KR20040028942A (el)
CN (2) CN1853722A (el)
AT (1) ATE406166T1 (el)
AU (1) AU2002319665B2 (el)
BR (1) BR0211365A (el)
CA (1) CA2454339C (el)
CY (1) CY1108562T1 (el)
DE (1) DE60228579D1 (el)
DK (1) DK1408981T3 (el)
ES (1) ES2312598T3 (el)
HK (1) HK1061526A1 (el)
IL (1) IL159913A0 (el)
MX (1) MXPA04000692A (el)
NZ (1) NZ530724A (el)
PT (1) PT1408981E (el)
WO (1) WO2003009853A1 (el)
ZA (1) ZA200400444B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432379B1 (en) * 2001-08-31 2008-10-15 Corcept Therapeutics, Inc. Methods for inhibiting cognitive deterioration in adults with down's syndrome
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3560493T3 (pl) 2013-11-25 2021-10-04 Corcept Therapeutics Incorporated Skondensowane oktahydroazadekaliny będące modulatorami receptora glukokortykoidowego
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
JP2020515563A (ja) 2017-03-31 2020-05-28 コーセプト セラピューティクス， インコーポレイテッド 子宮頸がんを処置するためのグルココルチコイドレセプターモジュレーター
US11273166B2 (en) 2017-06-13 2022-03-15 Monash University Methods and compositions for the treatment of obesity
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
BR112021010461A2 (pt) 2018-12-19 2021-08-24 Corcept Therapeutics Incorporated Formulação e dose unitária para administração oral de relacorilante
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN113490496A (zh) 2019-02-22 2021-10-08 科赛普特治疗学股份有限公司 一种杂芳基-酮稠合氮杂萘烷糖皮质激素受体调节剂瑞拉可兰的治疗用途
US20220288091A1 (en) * 2019-03-18 2022-09-15 Lynnette K. NIEMAN Method for Improving Insulin Sensitivity
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
IL297840A (en) 2020-05-06 2023-01-01 Corcept Therapeutics Inc Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
AU5729098A (en) * 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
ATE332696T1 (de) * 1997-10-06 2006-08-15 Univ Leland Stanford Junior Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
NZ507449A (en) 1998-05-15 2003-08-29 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the treatment of dementia
CA2363784A1 (en) * 1999-05-19 2000-11-30 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
DK1408981T3 (da) 2009-01-12
ES2312598T3 (es) 2009-03-01
US20030027802A1 (en) 2003-02-06
MXPA04000692A (es) 2004-04-21
CA2454339A1 (en) 2003-02-06
KR20040028942A (ko) 2004-04-03
EP1408981B1 (en) 2008-08-27
EP1408981A4 (en) 2005-06-08
CN1547473A (zh) 2004-11-17
US6680310B2 (en) 2004-01-20
AU2002319665B2 (en) 2006-09-21
DE60228579D1 (de) 2008-10-09
IL159913A0 (en) 2004-06-20
NZ530724A (en) 2005-09-30
ZA200400444B (en) 2005-03-30
BR0211365A (pt) 2004-09-21
HK1061526A1 (en) 2004-09-24
CA2454339C (en) 2012-01-10
PT1408981E (pt) 2008-12-04
CN1853722A (zh) 2006-11-01
ATE406166T1 (de) 2008-09-15
EP1408981A1 (en) 2004-04-21
JP2004537563A (ja) 2004-12-16
WO2003009853A1 (en) 2003-02-06
JP2009102413A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
CY1108562T1 (el) Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες
IL139672A (en) Glucocorticoid receptor antagonists for the tretment of dementia
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
NO20070723L (no) Progesteron reseptormodulatorer inneholdende pyrrol-oksindolderivater og deres anvendelse
DK1023074T3 (da) Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
AU2003228283A1 (en) Quinazolinone modulators of nuclear receptors
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
UY27870A1 (es) Nuevos derivados de quinuclidina-amida
HK1068783A1 (en) Methods for increasing the therapeutic response to electroconvulsive therapy ("ect")
DK1682545T3 (da) Imidazopyridinsubstituerede tropanderivater med CCR5 receptorantagonistaktivitet til behandling af HIV og inflammation
UY27850A1 (es) Nuevos carbamatos de quinuclidina y composiciones farmacéuticas que los contienen
EP2032127A4 (en) TREATMENT OF PSYCHOLOGICAL PATHOLOGIES USING M1 MUSCARINIC RECEPTOR ANTAGONISTS
HK1062533A1 (en) Methods for inhibiting cognitive deterioration in adults with down's syndrome
DK1467762T3 (da) Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis
WO2004069202A3 (en) Antiglucocorticoids for the treatment of postpartum psychosis
IL158744A0 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
UA98938C2 (ru) Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1
WO2005009382A3 (en) Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
WO2002020526A3 (en) Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents